Lundbeck Beat Even the Highest Estimate on All Three Lines, Inderes Reports

H. Lundbeck reported third-quarter revenue of DKK 6.6 billion on Tuesday, up 7 percent at constant exchange rates from a year earlier.

H. Lundbeck A/S, the Danish drugmaker focused on brain diseases, reported results for the quarter ended September 30, 2026. The report covered the first nine months of 2026.

Adjusted earnings before interest, taxes, depreciation and amortization (adjusted EBITDA) rose to DKK 2.26 billion in the quarter. It rose 17 percent at constant exchange rates (CER) and 10 percent in Danish kroner.

Adjusted earnings were DKK 1.71 a share, up 19 percent in kroner. Reported earnings were DKK 1.28 a share.

Every main line cleared the top of the range

All three main lines beat even the highest estimate in Lundbeck's company-compiled consensus, Inderes reported. The consensus, collected by Lundbeck from 12 analysts, expected revenue of DKK 6.35 billion.

Its highest revenue estimate was DKK 6.53 billion, below the DKK 6.6 billion reported. Adjusted EBITDA topped a highest estimate of DKK 2.1 billion, and adjusted earnings topped DKK 1.59 a share.

Against the consensus mean, adjusted EBITDA beat the expected DKK 1.95 billion by about 16 percent, a TickerGrove calculation. Expected adjusted earnings were DKK 1.49 a share.

Vyepti led a broad brand quarter

Vyepti, the migraine treatment sold as eptinezumab, posted third-quarter revenue of DKK 1.67 billion. It rose 44 percent at CER, ahead of the DKK 1.57 billion expected, Inderes reported.

Rexulti, an antipsychotic, posted third-quarter revenue of DKK 1.77 billion, up 6 percent at CER. That edged past the DKK 1.75 billion expected, according to Inderes.

Brintellix/Trintellix, an antidepressant, posted DKK 1.06 billion in the quarter, down 1 percent at CER. The Abilify LAI franchise - long-acting injectable schizophrenia treatments - posted DKK 988 million, up 2 percent at CER.

Strategic brands together posted DKK 5.49 billion in the quarter, up 12 percent at CER. They were 83 percent of third-quarter revenue.

Nine months show the same engine, plus a one-off

For the first nine months, revenue reached DKK 20.19 billion, up 13 percent at CER and 9 percent in kroner. Strategic brands reached DKK 15.95 billion, up 16 percent at CER, or 79 percent of revenue.

Vyepti posted DKK 4.53 billion over nine months, up 45 percent at CER, with United States revenue up 46 percent. Rexulti posted DKK 5.07 billion, up 13 percent at CER.

United States revenue reached DKK 11.22 billion over nine months, up 18 percent at CER. Excluding a planned one-time inventory build, underlying nine-month revenue growth was 11 percent at CER.

The build was DKK 470 million of stock placed in the 27 partner markets in the first quarter of 2026. It lifted reported growth without reflecting end demand in those markets.

"We delivered strong growth in the first nine months of 2026, led by the continued impressive performance of Vyepti," President and Chief Executive Charl van Zyl said. "This momentum underpins our decision to raise our full-year guidance for 2026."

In September, Japan's health ministry (MHLW) granted marketing authorization for eptinezumab, sold as Vyepti. The authorization, announced on September 16, covers prevention of migraine attacks in adults.

Guidance rose again, with a margin trim

Lundbeck now expects full-year revenue growth of 11 to 12 percent at CER, guidance raised from 7 to 9 percent. Adjusted EBITDA growth guidance rose to 15 to 19 percent, from 8 to 14 percent.

It was the second guidance increase this year, following one in May, according to Inderes. The adjusted EBITDA midpoint lift is about six percentage points, a TickerGrove calculation.

Research and development spending guidance narrowed to DKK 5.6 to 5.7 billion, from DKK 5.6 to 5.9 billion. The company said the narrowing reflects spending phasing, not lower ambition.

The adjusted gross margin guide was trimmed to 86 to 87 percent, from around 87 percent before. Lundbeck cited growth weighted toward lower-margin products, particularly Vyepti, plus partner-market commission fees.

Fourth-quarter revenue growth is expected to moderate from the nine-month pace, Lundbeck said. The first reason is that the DKK 470 million first-quarter inventory build will not recur.

Generic competition for Trintellix starts in December 2026, the company added. Competition for Rexulti is also intensifying, it said.

Shares hit a record on the beat

Shares were up around 5 percent by 11:16 GMT on Tuesday, hitting a new record high, Reuters reported. The snapshot is intraday, not a closing price.

What remains unknown

What remains unknown starts with the fourth quarter. Lundbeck has not quantified how much Trintellix generics and Rexulti competition will slow growth.

Whether Vyepti can sustain growth near this pace in 2027 is also unknown. Whether consensus estimates rise to meet the new guidance is also unknown.

The fourth quarter will test the raise

What to watch: fourth-quarter revenue against the three headwinds Lundbeck named, and whether the adjusted gross margin lands inside 86 to 87 percent. Watch also updated analyst estimates after the company-compiled consensus reset.